%0 Journal Article
%T Risk allocation of adult patients with non-M3 acute myeloid leukemia
%A A. Venditti
%A F. Buccisano
%A L. Maurillo
%A M. I. Del Principe
%J Drugs and Cell Therapies in Hematology
%D 2013
%I PAGEPress Publications
%R 10.4081/dcth.2013.83
%X In acute myeloid leukemia (AML), cytogenetic/genetic assessment is universally recognized as a critical step since karyotypic and/or molecular abnormalities have been consistently shown to play a major prognostic role. At the same time, it is also very well known that cytogenetic/genetic signature may fail in predicting individual patient¡¯s outcome. In this view, minimal residual disease (MRD) detection promises to become a valuable biomarker to assess the quality of response after chemotherapy and possibly outline post-remissional programs based on the individual risk of relapse. As a matter of fact, the choice of post-remission therapy for adults with AML still largely relies on the one size fits all principle, therefore there is confidence that MRD determination will help refine risk-allocation leading to more appropriate, risk-adapted post-remissional interventions. In the present review, we will discuss the impact of cytogenetics and genetics on outcome of patients with AML and the role that a biomarker such as MRD might have if incorporated in our current risk-assessment algorithms. A comprehensive biological risk-assessment including cytogenetic/genetic profile and MRD determination would possibly allow tailored therapeutic strategies to be adopted, avoiding situations of under or overtreatment.
%K acute myeloid leukemia
%K cytogenetics
%K genetics
%K minimal residual disease
%K flow cytometry
%K polymerase chain reaction.
%U http://www.dcth.org/dcth/article/view/3